EZH2 and epithelioid sarcoma: Inhibition of Enhancer of Zeste 2 (EZH2), a type of HMT, has been proven effective for metastatic or locally advanced epithelioid sarcoma and it is for this indication that the EZH2 inhibitor tazemetostat has been approved by the FDA [54].